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revealed a lower time-to-transplantation for PD versus HD 
patients (subhazard ratio: 2.34, p < 0.01, and 2.57, p < 0.01, 
respectively). The waiting time for placement in the trans-
plant waiting list was longer in HD than PD patients (330 
vs. 224 days, p < 0.01).
Conclusions The extensive use of PD did not lead to any 
statistically signiicant diference in mortality. Furthermore, 
PD was associated with lower time to transplantation. PD 
may be a viable option for large-scale dialytic treatment in 
the advanced chronic kidney disease population.
Keywords Dialysis survival · Hemodialysis · Advanced 
chronic kidney disease · Kidney transplantation · Peritoneal 
dialysis · Competing-risks model
Introduction
Hemodialysis (HD) and peritoneal dialysis (PD) are the 
two common forms of dialysis therapy for end-stage renal 
disease (ESRD). Although PD is a well-established treat-
ment modality for advanced chronic kidney disease ofer-
ing several potential beneits, it is underused in Western 
countries [1]. In 2008, only 11% of the dialysis population 
was treated with PD worldwide [2]. PD prevalence varies 
signiicantly between regions. The proportion of dialysis 
patients on PD reaches the 79% in Hong Kong [2]. Con-
versely, PD initiation in the United States has traditionally 
been low, never exceeding 15 to 16% of incident or preva-
lent maintenance dialysis patients [1]. In Italy, recent data 
from the Italian Study Group of Peritoneal Dialysis have 
reported an incidence of PD modality of approximately 
20% with a prevalence of 15% [3]. The underuse of PD 
does not seem justiied in terms of safety and efectiveness; 
it could be explained, instead, by a complex set of clinical, 
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organizational, economic as well as patient-related fac-
tors favoring HD use [4]. Indeed, data derived from both 
national registries and large observational studies agree that 
the survival rate of patients treated with both modalities is 
at least comparable [5, 6].
A randomized controlled clinical trial on dialysis modal-
ity was attempted in the Netherlands, but only 38 of 773 
eligible subjects provided consent to be randomized to 
receive the diferent treatment options [7]. Currently avail-
able survival data are virtually all observational and thus 
afected by confounding factors and limitations [8]. Indis-
putable evidence for beneicial efects on survival can be 
obtained only from randomized clinical trials, but it is 
unrealistic to expect such an initiative in the near future [9]. 
Therefore, the acquisition of reliable and comprehensive 
observational data is of the utmost importance to reliably 
examine the clinical consequences of radical modiications 
in dialysis therapy [9]. Over the last 10–15 years, as overall 
survival of dialysis patients has steadily improved and sta-
tistical methods to analyze observational data have evolved, 
a pattern of virtual equivalence in survival between patients 
on HD versus PD has emerged [8]. Previous studies showed 
that age ≥65 years, frailty, cardiovascular disease, and 
diabetes mellitus could worsen survival outcomes in PD 
compared to HD patients [10–12]. However, focusing on 
transplantation outcomes, PD patients could beneited from 
a higher rate of kidney transplantation and shorter time-to-
transplantation with respect to their HD counterparts [13].
Further research is needed to improve PD uptake, and to 
support appropriate and patient-centered decision-making 
in the real care context to improve patient survival and well-
being. The use of advanced statistical analysis techniques 
may afect the quality of studies and has the potential to 
highlight the most efective strategies for improvement.
Since 2008, a concerted efort has been made in the 
healthcare services of the Autonomous Province of Trento 
to expand the use of PD through the implementation of a 
capacity building program [14]. Following the introduc-
tion of this strategy, the incidence of PD patients progres-
sively increased to 47% in 2013. Signiicantly, the preva-
lence of PD patients grew to 20%, which is higher than the 
Italian healthcare system average. Based on these results, 
the present study was designed to analyze the outcomes 
related to the increased use of PD over the 7-year program, 
and compare PD and HD in terms of patient mortality and 
time-to-transplantation.
To overcome limits due to the retrospective design of 
the study, a propensity score model was implemented to 
assure matching of the two treatment groups. Furthermore, 
survival data in ESRD patients were analyzed by compet-
ing-risks regression [15], since in these patients death and 
transplant act as competing events (i.e. the occurrence of 
one event hinders or modiies the occurrence of the other).
Methods
Treatment center
In 2008 the new clinical leadership of the Nephrology and 
Dialysis Unit and the implementation of evidence-based 
policies led to the initiation of a large-scale PD program. 
The program involved physician training in the use of PD, 
systematic pre-dialysis information and education [14], and 
clinical path standardization across the province. The man-
agement change was supported by promoting teamwork, 
collaboration, and performance feedback.
Data collection and patients
This study was an observational, retrospective cohort study. 
Data were collected from 487 patients treated at the Unit 
of Nephrology of the Santa Chiara Hospital in Trento 
from January 1, 2008, to December 31, 2014. Patients 
were observed until September 30, 2015, granting a mini-
mum follow-up period of 9 months. Patients decided to 
undergo treatment on a voluntary basis, after a detailed 
informative discussion and clinical evaluation with physi-
cians and nurses: 334 patients chose HD and 153 PD treat-
ment. All patients gave informed consent for the collec-
tion and processing of data in anonymous form. Exclusion 
criteria were: previous transplantation, or death within 30 
days from the start of the treatment (i.e. in the adjustment 
to therapy period). Patients who chose to change dialysis 
treatment modality during the study period were censored. 
To correct the analysis for baseline covariates that could 
potentially afect the choice of dialysis modality, a propen-
sity score model was implemented [16]. The estimation of 
the propensity score was performed with a logistic regres-
sion model based on region of common support including 
gender, age-group, cardiovascular disease, diabetes, chronic 
obstructive pulmonary disease (COPD), chronic liver dis-
ease, cancer, and hypertension as included variables. The 
matching between HD and PD patients was done with the 
Kernel Matching method. Distribution of baseline covari-
ates before matching was not uniform for diabetes mellitus, 
while after propensity score matching it was uniform for 
all covariates. Demographic characteristics, survival, and 
comorbidities data were collected at the start of the dialytic 
therapy and derived from the Provincial Register of Dialy-
sis Patients.
Statistical analyses
Survival analysis was performed using competing-risks 
regression models, according to the method of Fine 
and Gray [17]. The model is based on cumulative inci-
dence functions and subdistribution hazards risk (SHR) 
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functions. For the survival study, the event of interest was 
death and the competing event was transplantation. Crude 
and adjusted regression models were computed. Adjust-
ment was performed for age-group (<65 vs. ≥65 years), 
cardiovascular disease, diabetes mellitus, and arterial 
hypertension.
In order to evaluate the eiciency of the transplant 
process (i.e. time to placement on the transplant waiting-
list, and time-to-transplantation), competing-risks regres-
sion models were calculated, considering transplant as 
the event of interest and death as the competing event. 
Crude and adjusted by age-group regression models were 
calculated. In the subgroup of patients on the transplant 
waiting list (54 HD patients and 49 PD patients) difer-
ences in waiting time for placement in the list and in call 
time-to-transplantation after placement in the list were 
assessed by Mann–Whitney U test. Data were expressed 
as median and interquartile range (IQR) for not normally 
distributed data, and number and percentage for categori-
cal data. Categorical data were compared by the chi-
squared test and continuous data by the Mann–Whitney 
U test.
A p-value less than 0.05 indicated statistical signii-
cance. All analyses were performed with Stata statistical 
software, version 13.0 (StataCorp, Texas 77845 USA).
Results
Patient characteristics and clinical data
Following screening for exclusion criteria and propensity 
score matching, 279 HD patients and 132 PD patients 
were analyzed. The characteristics of the two groups of 
patients after the propensity score matching are shown 
in Table 1. The two groups were uniform for each of the 
considered features. The glomerular iltration rate at the 
start of dialysis was between 4.5 and 6 ml/min (Chronic 
Kidney Disease Epidemiology Collaboration formula). 
The Kt/V ratio (urea clearance multiplied by treatment 
time/urea distribution volume) was maintained in the 
range of the Kidney Disease Outcomes Quality Initia-
tive (KDOQI) guidelines (>1.2 per session in HD, 2.0 
per week in PD). Regarding HD, 204 of 279 HD patients 
(73%) were treated by istulas or grafts, and 75 (27%) 
by tunneled central venous catheter. Regarding PD, 86 
of 132 PD patients (65%) adopted automated peritoneal 
dialysis, while 46 (35%) practiced continuous ambulatory 
peritoneal dialysis. More than 90% of the patients were 
put on dialysis after a period of pre-dialysis education 
and care at the hospital outpatient clinic.
Survival analysis—death as event of interest
Death occurred in 102 (37%) HD patients versus 46 (35%) 
PD patients. As shown in Fig. 1, the cumulative incidence 
of death was slightly but not signiicantly higher in PD 
patients than in HD patients (SHR = 1.09, p = 0.62). The 
risk of death in PD patients did not change signiicantly 
(SHR = 1.34, p = 0.10) after adjustment for age-group, car-
diovascular disease, diabetes mellitus, and arterial hyper-
tension. Adjusted regression model values with covariate 
contributions are reported in Table  2. Aging (≥65 years) 
and cardiovascular disease increased the SHR of death, 
while arterial hypertension decreased it. Diabetes mellitus 
had no statistically signiicant efect. However, the con-
founders did not signiicantly modify the risk of death for 
PD patients in comparison to HD patients.
Survival analysis—transplantation as event of interest
Transplantation occurred in 42 (32%) PD patients com-
pared to 47 (17%) HD patients. As shown in Fig.  2, the 
cumulative incidence of transplant was signiicantly higher 
in PD patients than HD patients (SHR = 2.34, p < 0.01). 
After adjustment for age-group, the SHR increased to 2.57 
(Table 3). At multivariate analysis, age ≥65 years signii-
cantly decreased the likelihood of receiving a transplant 
(Table 3).
Time-to-transplantation
A greater proportion of PD patients (49/132, 37%) were 
on the transplant waiting list than HD patients (54/279, 
19%). The median time for placement on the transplant 
Table 1  Characteristics of the study population after propensity 
score matching
COPD chronic obstructive pulmonary disease, HD hemodialysis, IQR 
interquartile range, PD peritoneal dialysis
HD, n (%) PD, n (%) p
Total patients 279 132
Males 194 (70) 90 (68) 0.78
Females 85 (30) 42 (32) 0.78
Cardiovascular disease 126 (45) 56 (42) 0.60
Diabetes mellitus 94 (34) 33 (25) 0.08
COPD 44 (16) 20 (15) 0.87
Chronic liver disease 29 (10) 15 (11) 0.77
Cancer 41 (15) 19 (14) 0.94
Arterial hypertension 234 (84) 105 (80) 0.28
Age at start of dialysis <65 years 107 (38) 56 (42) 0.43
Age at start of dialysis ≥65 years 172 (62) 76 (58) 0.43
Median age at start of dialysis, years 
[IQR]
69 [59–78] 69 [54–76] 0.20
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waiting list was signiicantly longer (p < 0.01) in HD [330 
days (IQR 222–663)] than PD patients [224 days (IQR 
178–363)]. The median time to receive the call for trans-
plantation after placement in the waiting list was slightly 
but not signiicantly (p = 0.35) longer in HD [216 days (IQR 
107–424)] than in PD patients [155 days (IQR 108–322)].
Discussion
Broadening the evidence using comparative studies of 
dialysis outcomes and their impact on ESRD is essential to 
drive changes in care patterns and to help the nephrology 
Fig. 1  Cumulative incidence function of hemodialysis (HD, continu-
ous line) and peritoneal dialysis (PD, dashed line) patients from 2008 
to 2014, provided by crude (left) and adjusted (right) competing-risks 
regression models. In the model the event of interest was death and 
the competing event was transplantation. Adjustment was performed 
for age-group, cardiovascular disease, diabetes mellitus, and arterial 
hypertension
Table 2  Subdistribution hazard ratios of PD patients compared to 
HD patients according to the multivariate competing-risks regression 
model
CI conidence interval, HD hemodialysis, PD peritoneal dialysis, 
SHR subdistribution hazard ratio
Adjusted competing-risks regression—event of interest death
SHR (95% CI) p
PD compared to HD 1.34 (0.95–1.91) 0.10
Age ≥65 years 4.22 (2.59–6.88) <0.01
Cardiovascular disease 2.08 (1.42–3.04) <0.01
Diabetes mellitus 1.17 (0.82–1.65) 0.39
Arterial hypertension 0.46 (0.30–0.71) <0.01
Fig. 2  Cumulative incidence function of hemodialysis (HD, continu-
ous line) and peritoneal dialysis (PD, dashed line) patients from 2008 
to 2014, provided by crude (left) and adjusted (right) competing-risks 
regression models. In the model the event of interest was transplanta-




community relect critically on its practices. The present 
study aimed to evaluate the efects of an increased use 
of PD in the Autonomous Province of Trento in terms of 
survival and time to transplantation. This was performed 
within a framework of outcome assessment to improve 
the quality of care and quality of life of patients. In this 
study we analyzed data from 279 HD patients and 132 PD 
patients over a period of 7 years with a minimum follow-
up of 9 months. Since the study was an observational ret-
rospective cohort study, the power of the results was poten-
tially limited.
It is well known that the comparison of two diferent 
treatments under real life conditions (i.e. outside the con-
text of a randomized clinical trial) is afected by the ‘con-
founding by indication’ problem, which needs to be prop-
erly addressed. Therefore, we constructed a propensity 
score model [16] to match PD and HD patients. The score 
allowed us to analyze the baseline covariates that could 
potentially afect the choice of dialysis modality and thus to 
balance the risk of positive selection of the PD population. 
After propensity score matching we obtained two large 
patient groups, which were homogenous regarding clinical 
characteristics, modality and length of treatment.
The comparative study was performed using competing-
risks regression models. Accounting for competing risk 
events permits the simultaneous analysis of outcomes and 
avoids overestimation of cumulative incidences [15]. In our 
study, the competing-risks model was applied twice: con-
sidering death as the event of interest and transplantation 
as the competing event, and vice versa. Survival analysis 
did not reveal any evidence of diference between PD and 
HD in terms of mortality. Consistently, crude and adjusted 
regression models for survival revealed no signiicant dif-
ference in terms of cumulative incidence functions between 
patient groups.
Although disputed by a recent analysis [18], the litera-
ture generally reports better survival for PD patients com-
pared to HD patients during the irst years of treatment 
[19]. Our study performed on two samples equivalent for 
frailty and complex disease characteristics did not conirm 
this inding. Indeed, PD patients showed a proportional and 
slightly higher incidence of death than HD patients during 
the whole treatment course, but without any statistically 
meaningful diference.
Aging (≥65 years) and cardiovascular disease increased 
the SHR of death. However, these confounders did not 
signiicantly modify the risk of death in PD patients with 
respect to HD patients. The issue of aging and cardiovas-
cular disease in PD patients is still debated in the litera-
ture [20]. Some studies conducted with diferent methods 
reported a higher risk of death in PD patients than HD 
patients, which increased with aging and cardiovascular 
disease [10, 21, 22]. In contrast, Buemi et al. reported that 
in elderly and cardiac patients, PD was actually preferable, 
because in comparison with HD it reduced the hemody-
namic stress experienced by the patient and the incidence 
of hypotension [23].
Although diabetes is recognized as a confounding vari-
able able to afect survival in PD versus HD patients, our 
study did not result in an increased risk of death for ESRD 
patients. A recent systematic review analyzed mortality 
outcomes in diabetic patients who underwent HD or PD. 
The analysis of 25 observational studies led to the conclu-
sion that the available evidence was inconsistent, because 
survival varied across study designs, follow-up periods, and 
patient subgroups [12].
Our results showed that hypertension decreased the 
risk of mortality in ESRD patients, but it did not afect 
the survival diferences between the two dialytic treat-
ments. The explanation for this inding is still controver-
sial. Some reports have indicated a paradoxical associa-
tion between hypertension and mortality in hemodialysis 
patients. According to this, a normal to low blood pressure 
seems associated with poor outcome, whereas high pres-
sure potentially confers survival advantages, a phenomenon 
termed ‘reverse epidemiology’ [24].
Hence, confounders analysis in a real clinical context 
showed that major clinical complications did not change 
the cumulative incidence of death in the two patient groups 
in a meaningful way. Indeed, the two treatment modalities 
displayed a substantial equivalence, apart from a small non-
signiicant negative trend in the PD group.
With respect to transplantation, the literature shows that 
PD commonly registers a higher rate of kidney transplanta-
tion [25]. According to data from the Italian national reg-
isters, this result seems to be due to the younger age of PD 
patients and the higher prevalence of irst dialysis experi-
ence [26]. In our study, where the number of patients who 
could undergo PD was enlarged and patient age was com-
parable between the two groups, PD nonetheless had a 
reduced time-to-transplantation. Crude and adjusted regres-
sion models for transplantation revealed a signiicantly 
lower time-to-transplantation for PD compared to HD.
Table 3  Subdistribution hazard ratios of PD patients compared to 
HD patients according to the multivariate competing-risks regression 
model
CI conidence interval, HD hemodialysis, PD peritoneal dialysis, 
SHR subdistribution hazard ratio
Adjusted competing-risks regression—event of interest transplanta-
tion
SHR (95% CI) p
PD compared to HD 2.57 (1.68–3.92) <0.01
Age ≥65 years 0.06 (0.03–0.12) <0.01
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According to our analysis, this inding seems mainly 
attributable to the reduction in the time to be placed on the 
waiting list for PD patients. The tendency to reduce time to 
transplantation for PD patients was conirmed by the call 
time to transplant, although the diference in this case was 
not signiicant. This inding could be related to a diferent 
proile of PD patients. Patients who undergo this method 
tend to be more empowered, and to pursue their care plan 
by themselves. Having a strong social support network and 
being functionally able is strongly associated with choosing 
PD [27]. This attitude can be translated into a more ei-
cient treatment and a better planning of the examinations 
necessary for inclusion in the transplantation waiting list. 
Moreover, these patients have to manage their own treat-
ment daily, which can serve as a strong incentive to obtain 
quick inclusion in the list. Vice versa, the frequent hospi-
tal admissions required for HD may negatively afect the 
planning of the examinations necessary for inclusion in the 
transplantation waiting list.
Although not statistically signiicant, the HD slower 
time in call-to-transplantation could be partially explained 
by the fact that these patients had a greater tendency to ane-
mia and more likely required blood transfusion with greater 
use of erythropoiesis-stimulating agents due to an increase 
in panel reactive antibody [28]. The presence of antibodies 
generated by frequent transfusions may therefore hinder the 
inding of a matching organ for transplantation, prolonging 
the waiting time in HD patients.
Overall our indings should be taken into account to 
improve clinical practice and management of modality 
choice. This may be part of a general improvement strat-
egy aimed to maximize quality of life, patient-reported out-
comes, and cost-savings [29, 30].
Conclusions
The aim of this study was to assess outcomes of survival 
and time-to-transplantation in the presence of an exten-
sive use of PD in patients with ESRD in the Autonomous 
Province of Trento. Our data did not show diferences 
in long-term survival between patients treated with PD 
and with HD. Diferently, PD patients seemed to beneit 
in terms of reduced time for placement on waiting list to 
transplantation.
Our indings support the wider adoption of PD thanks 
to its feasibility, and the evidence of positive outcomes and 
far-reaching beneits for patients. These reported results 
and the analysis performed should help in devising future 
studies with similar methods of competing risk survival 
analysis and management strategies to achieve an improve-
ment in the outcomes of patients undergoing dialysis care.
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